Recurrent Uterine Sarcoma
15
0
0
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
13.3%
2 terminated out of 15 trials
86.7%
+0.2% vs benchmark
0%
0 trials in Phase 3/4
62%
8 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (15)
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer